Nemus Bioscience, Inc. (OTC:NMUS)
Industry: Healthcare

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases; and an agreement with Pharmaceuticals International Inc. to develop a sterile eye drop dosage formulation of NB1111 for human dosing. The company was founded in 2012 and is headquartered in Long Beach, California.

Current Quote*
Last: $0.510
Change: -0.005
Book: $Unk
Volume: 91,688

As Of: 02/15 13:34 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol NMUS

Graphs for NMUS


3 Month Graph


6 Month Graph


1 Year Graph